Contacts

Emma Danks

Partner

Read More

Richard Faichney

Senior Counsel

Read More

Deepti Patankar

Senior Associate

Read More

Callum McLean

Associate

Contacts

Emma Danks

Partner

Read More

Richard Faichney

Senior Counsel

Read More

Deepti Patankar

Senior Associate

Read More

Callum McLean

Associate

5 May 2023

Advising ATL Technology on its acquisition of Gyrus Medical LTD. Manufacturing Operations

We have advised Endeavour-backed ATL Technology (ATL), a fast-growing provider of outsourced design, development and manufacturing services to the medical devices market, on its acquisition of the manufacturing operations of Gyrus Medical Limited (Gyrus) from Olympus Winter & Ibe GmbH (Olympus Surgical Technologies Europe). 

Founded in 1993, ATL focuses on providing its customers with world class engineering solutions to provide best in class medical device products. The company offers contract engineering capabilities and global resources to manufacture those products in every region around the world. 

Gyrus, located in Cardiff, is also a device outsourcer and has worked with medical device original equipment manufacturer customers to develop and manufacture innovative solutions to improve patient care. This strategic acquisition will increase both ATL's global footprint and capabilities. 

Commenting on the acquisition, Head of Corporate M&A Emma Danks said: "This is a strategic acquisition that allows Gyrus' capabilities to be incorporated into ATL's existing offerings and to expand ATL's global footprint deeper into the UK and across Europe. We are delighted to have supported ATL on this multi-jurisdictional transaction, and we look forward to seeing what the combination will continue to offer to the medical devices industry."

ATL's CEO, Joe Glover commented: "We are enthusiastic about welcoming the Gyrus team to ATL. Their significant engineering capabilities will enhance ATL’s existing resources, allowing ATL to continue its impressive growth rates. We are thankful to the Taylor Wessing team for their insightful advice and outstanding services. Their life sciences sector expertise along with deep private equity knowledge were integral to the transaction as they clearly understood our needs and delivered exceptional guidance throughout."  

The team was led by partner Emma Danks, senior counsel Richard Faichney, senior associate Deepti Patankar and associate Callum McLean. Further support was provided by: 

Commercial Technology and Data
Partners Victoria Hordern and Sian Skelton, senior associate Mary Rendle, and associate Miles Harmsworth

Corporate
Trainee David Stuart and paralegal Jamie Mehta

Employment, Pensions and Mobility
Partners Helen Farr and Anna Taylor, senior counsel Vikki Wiberg, senior associate Afshan Mallik, and associate Zeinab Harb

Patents
Partner Adrian Toutoungi and senior associate Sebastian Allen-Johnstone

Real Estate
Partner Emma Oakley and associates Charlie Marshall and Francesca Gibbs

Tax and Incentives
Partner Graham Samuel-Gibbon and senior associate Bridget Winters

Call To Action Arrow Image

Latest insights in your inbox

Subscribe to newsletters on topics relevant to you.

Subscribe
Subscribe

Related Insights

Corporate/M&A & capital markets

Advising Bridgepoint on its sale of one.network

7 August 2023

by multiple authors

Click here to find out more
Corporate/M&A & capital markets

Advising APCO Worldwide as it pushes into financial communications with Camarco purchase

19 April 2023

by multiple authors

Click here to find out more
Corporate/M&A & capital markets

Advising Jagex, one of the UK’s largest video game developers and publishers, on its sale

1 March 2021

by multiple authors

Click here to find out more